China Biologic Pays $87 Million for Additional 20% Stake in Subsidiary

China Biologic Products, a plasma-based biopharma, will pay $87.1 million to purchase an additional 20% stake in Guizhou Taibang Biological Products Co.. The acquisition raises China Biologic's holding in Guizhou Taibang from 56% to 76%. In March, Guizhou Taibang completed the GMP certification of its new facility, making the company compliant with China's more stringent plasma production standards. More details.... Stock Symbol: (NSDQ: CBPO) Share this with colleagues: // //